Please login to the form below

Not currently logged in
Email:
Password:

gemcitabine

This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

AstraZeneca’s Imfinzi plus chemotherapy accepted for Priority Review in the US

Data taken from the TOPAZ-1 phase 3 trial demonstrated Imfinzi plus chemotherapy (gemcitabine plus cisplatin) reduced the risk of death by 20% compared to the use of chemotherapy alone.

Latest news

More from news
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest Intelligence

  • The rise of chronic disease in BRIC markets The rise of chronic disease in BRIC markets

    For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....